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Abstract
Protein misfolding caused by inherited mutations leads to loss of protein function and potentially toxic ‘gain of function’,
such as the dominant P23H rhodopsin mutation that causes retinitis pigmentosa (RP). Here, we tested whether the AMPK
activator metformin could affect the P23H rhodopsin synthesis and folding. In cell models, metformin treatment improved
P23H rhodopsin folding and traffic. In animal models of P23H RP, metformin treatment successfully enhanced P23H traffic to
the rod outer segment, but this led to reduced photoreceptor function and increased photoreceptor cell death. The
metformin-rescued P23H rhodopsin was still intrinsically unstable and led to increased structural instability of the rod outer
segments. These data suggest that improving the traffic of misfolding rhodopsin mutants is unlikely to be a practical therapy,
because of their intrinsic instability and long half-life in the outer segment, but also highlights the potential of altering trans-
lation through AMPK to improve protein function in other protein misfolding diseases.
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Introduction
Inherited mutations in rhodopsin (RHO), the light sensitive pro-
tein of rod photoreceptor cells, are the most common cause of
autosomal dominant retinitis pigmentosa (adRP). Rhodopsin is
the archetypal G protein-coupled receptor (GPCR) comprising a
348 amino acid apoprotein rod opsin covalently linked with the
vitamin A derived chromophore 11-cis-retinal (1). Rod opsin pro-
tein is an integral membrane protein with an N-terminus that is
located intradiscally (corresponding to the extracellular location
of other GPCRs), a C-terminus that is an intracellular and seven
transmembrane (TM) helices (2). Most rhodopsin mutations,
such as P23H the most common mutation in North America, are
found in the intradiscal or transmembrane domains of rhodop-
sin and cause rhodopsin misfolding (Class II mutations) (3). An
understanding of the molecular mechanisms underlying Class
II rhodopsin mutants came from cell culture models which
showed that misfolded rod opsin is retained in the endoplasmic
reticulum (ER), as opposed to wild-type (WT) normal protein
which translocates to the plasma membrane. These results sug-
gested the existence of an ER quality control machinery that
does not permit further traffic of misfolded rod opsin (4,5).
Misfolded rod opsin is retrotranslocated from the ER and
degraded via the ubiquitin proteasome system; however, non-
degraded mutant rod opsin can spontaneously aggregate and
form intracellular inclusions (6,7). Mutant rod opsin can also
exert a dominant-negative effect on the processing of WT rod
opsin (6,8) and can activate the unfolded protein response (UPR)
(9).
In photoreceptors, correctly folded rod opsin is transported
from the inner segments (IS) to the rod outer segments (ROS)
and inserted in densely packed disks. Proper folding of rod
opsin is a prerequisite for visual transduction since the co-
ordination of the natural ligand 11-cis-retinal within the fully
folded opsin generates the rhodopsin photopigment. Apart
from abolishing rhodopsin function, and of greater pathological
significance, misfolding also leads to photoreceptor cell death.
In animal models, P23H rhodopsin is localised primarily to rod
IS and outer nuclear layer (ONL) and ER stress and dominant-
negative mechanisms have been observed (9–11). However,
some P23H can traffic to the ROS whereby retinal degeneration
is accelerated by light (12,13). Another potential disease mech-
anism is the destabilisation of ROS architecture (10,14,15). For
example, in the P23H knock-in (KI) mouse model, over 90% of
mutant rhodopsin is degraded, whereas the remaining protein
can escape the ER and traffic to the ROS where it disrupts ROS
disk formation, affecting stability and resulting in photorecep-
tor vulnerability and death (14–16).
The high metabolic demand and complex architecture of the
retina requires strict regulation of proteostasis (protein homeo-
stasis) for protection against several insults, including those
arising from protein misfolding (reviewed in (17)). Similar to
other neurodegenerative diseases, the toxic-gain-of-function ef-
fect of mutant rhodopsin, could also reflect the incapacity of
photoreceptors to maintain proteostasis. Therefore, a number
of therapeutic approaches have attempted to manipulate pro-
teostasis mechanisms to reduce rhodopsin aggregation, en-
hance the degradation of mutant rhodopsin, stimulate
autophagy or correct misfolding. For instance, pharmacological
chaperones, kosmotropes (or chemical chaperones) and mo-
lecular chaperone inducers have been found to counteract
some of the effects of the P23H mutation in cells (6,18–21).
Additionally, drugs such as arimoclomol and Hsp90 inhibi-
tors that stimulate the cell stress responses in the retina, can
protect against photoreceptor cell death in transgenic rats ex-
pressing P23H rhodopsin by reducing P23H aggregation (22,23).
In contrast, pharmacological chaperones, such as 11- and 9-cis-
retinal, can improve P23H rod opsin folding in cells if they are
present during rod opsin biogenesis (6,19,20). Though vitamin A
supplementation improved the survival of rod cells in T17M
rhodopsin transgenic mice (24), 11-cis-retinal is highly abundant
in the retina and this approach has not been reported in P23H
animal models.
An alternative way to enhance folding and reduce aggrega-
tion of mutant proteins could be to target polypeptide chains
early in their synthesis on the ribosome. Studies have shown
that codon usage bias correlates with protein secondary struc-
ture through an effect on the translation elongation rate (25).
Different tRNAs have different concentrations in the cell result-
ing in slower ribosome recognition for the rare tRNAs and caus-
ing translational pausing. By slowing down peptide formation
in critical regions, the folding machinery is able to process the
protein more efficiently to improve overall folding. For instance,
an improvement was observed in mutant cystic fibrosis trans-
membrane conductance regulator (CFTR) trafficking following a
reduction in the elongation speed due to a triplet deletion (26).
Furthermore, in another study, mild inhibition of protein trans-
lation via pharmacological treatments improved the folding of
mutant CFTR and other polypeptides (27–29).
Protein translation is tightly controlled by adenosine 5’-
monophosphate activated protein kinase (AMPK), an enzyme
which acts as a sensor of cellular energy status by monitoring
the ratio of AMP:ATP and is referred to as the master regulator
of energy homeostasis (30). Two main mechanisms have been
proposed through which AMPK can regulate protein translation:
activation of the eukaryotic elongation factor 2 kinase (eE2K)
which phosphorylates its target eukaryotic elongation factor 2
(eEF2) leading to inhibition of the elongation step; and inhib-
ition of the mammalian target of rapamycin (mTOR), a serine/
threonine kinase that regulates the initiation step. The combin-
ation of these mechanisms leads to changes in the initiation
and elongation phases of mRNA translation (30,31).
Several drugs, including metformin, which is the first-line
treatment for type II diabetes and the most widely prescribed
antidiabetic drug, can activate AMPK. Metformin suppresses ex-
cessive hepatic glucose production, improves insulin sensitivity
and also protects against the cardiovascular complications of
diabetes as it inhibits lipid biosynthesis (32). Metformin report-
edly also has an anti-tumour effect and has been suggested as a
potential treatment for cancer and lymphoma (33–35).
In this study, we used a pharmacological approach to inves-
tigate the potential effect of mild inhibition of protein transla-
tion on mutant rod opsin disease mechanisms. Metformin
treatment improved P23H rod opsin folding and trafficking and
reduced P23H-related cell death in cell culture models; however,
the improvement in P23H traffic after metformin treatment
in vivo resulted in the reduced photoreceptor cell function and
increased photoreceptor cell death. Taken together, these re-
sults suggest that metformin can improve rhodopsin folding
and trafficking, but this structural rescue is transient and even-
tually enhances the instability of rod outer segments.
Results
Metformin enhances P23H rod opsin trafficking
The folding of mutant CFTR can be improved by inhibitors of
protein translation, elongation or initiation (28). The long-term
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use of such translational inhibitors, however, is limited because
prolonged inhibition of protein translation is toxic (27).
Therefore, we tested the ability of the AMPK activators, metfor-
min and 5-amino-1-b-D-ribofuranosyl-imidazole-4-carboxa-
mide (AICAR), to partially reduce translation and investigate the
hypothesis that mild inhibition of protein translation can im-
prove the traffic of misfolded rod opsin.
The effect of metformin was initially investigated on SK-N-
SH cells expressing P23H-GFP rod opsin. Following 18 h of
treatment, non-permeabilised cells were stained with the Rho-
4D2 antibody, which has an epitope in the extracellular
domain, to reveal the P23H-GFP that had trafficked to the cell
surface (Fig. 1A). Metformin treatment resulted in a general re-
duction of P23H-GFP rod opsin intracellular levels compared to
untreated cells and an increase in Rho-4D2 staining on the
plasma membrane. The same effect was also observed after
treatment with AICAR, and both compounds enhanced AMPK
phosphorylation (Fig. 1B and Supplementary Material, Fig. S1).
The enhanced traffic of P23H rod opsin in the presence of met-
formin and AICAR was confirmed by in-cell western analyses
of permeabilised and non permeabilised HA-P23H transfected
cells stained with the HA antibody which targets the extracel-
lular domain of rod opsin. (Fig. 1C and Supplementary
Material, Fig. S1). Both metformin and AICAR also improved
P23H rod opsin traffic in HEK293S cells (Supplementary
Material, Fig. S2).
To assess the turn-over of rod opsin at the plasma mem-
brane and whether this could be affected by metformin to alter
cell surface staining, we used a pulse of HA antibody labelling
on non-permeabilised, live cells and monitored the cell surface
expression of WT and P23H rod opsin at different time points of
chase (Fig. 1D and E). At time 0, WT rod opsin cell surface stain-
ing remained unchanged after metformin treatment while P23H
cell surface staining was significantly increased (Fig. 1D). P23H
rod opsin was more rapidly removed from the membrane, al-
most 50% after 3 h, than WT rod opsin, which was relatively sta-
ble (Fig. 1E). In both cases, metformin did not significantly affect
this turnover suggesting that the increased cell surface expres-
sion of P23H rod opsin at the membrane is due to increased traf-
fic and not altered turnover (Fig. 1E).
Expression of P23H rod opsin in SK-N-SH cells results in
enhanced cell death (19). Using a lactate dehydrogenase (LDH)
assay, we confirmed this finding with P23H-GFP expressing
cells. Importantly, after 48 h treatment with metformin (Fig. 1F)
or AICAR (Supplementary Material, Fig. S1) a significant reduc-
tion in the level of cytotoxicity compared to the untreated cells
was observed. These data suggest AMPK activation could also
protect these cultured cells from the toxic effects associated
with the P23H mutation.
The effect of metformin and AICAR on the activity of mTOR,
a downstream effector of AMPK that modulates protein trans-
lation, was investigated. Immunoblot analysis of the phos-
phorylation status of downstream targets of mTOR involved in
translation, such as S6 Ribosomal Protein, phospho-p70 S6
Kinase, phospho-eIF4B and 4E-BP1, showed reduction of
phosphorylation upon metformin and AICAR treatment
(Supplementary Material, Fig. S1). This would correlate with in-
hibition of mTOR signalling and a potential reduction in transla-
tion, as previously described for AMPK activation (36,37).
Emetine has been shown to improve CFTR folding through
mild inhibition of protein synthesis (28); therefore, emetine
was investigated to test if it also promotes P23H traffic to the
plasma membrane. In-cell western analysis showed that emet-
ine could also significantly increase P23H traffic to the plasma
membrane (Supplementary Material, Fig. S1). These data sug-
gest that inhibition of translation elongation increases P23H
rod opsin traffic; however, emetine was not as effective as
metformin, thus we concentrated the rest of the study on
metformin.
The improved traffic of P23H-GFP after metformin treat-
ment suggested enhanced folding of the protein in the ER,
allowing it to escape ER quality control. To assess this possibil-
ity, we tested the ability of P23H rod opsin to form functional
pigment to directly assess folding. UV-visible-absorption spec-
troscopy was performed for P23H rod opsin purified from a
tetracycline inducible HEK293S stable cell line (38) in the pres-
ence or absence of metformin during biogenesis. Metformin
treatment resulted in 6.4 fold increase in P23H pigment forma-
tion (Fig. 1G), indicating that in this model mild inhibition of
translation improves both the folding and trafficking of mutant
rhodopsin.
Metformin appeared to have no effect on the traffic of WT
rhodopsin. Moreover, no difference was observed in WT rhod-
opsin thermal stability, photobleaching profile or metarhodop-
sin decay when metformin was present during WT rhodopsin
expression, or when added to purified rhodopsin, confirming
that WT rhodopsin is not affected by metformin treatment
(Supplementary Material, Fig. S3). These data also suggest that
the effect of metformin on mutant rhodopsin traffic was not
caused by direct binding to rhodopsin, but is mediated by alter-
ing folding during biogenesis.
Metformin treatment enhances P23H trafficking in the
P23H knock-in mouse model
To confirm that metformin was able to affect P23H synthesis
and traffic in photoreceptors, we used the homozygous P23H KI
(RhoP23H/P23H) mouse that does not express WT rhodopsin. Since
antibody probes cannot differentiate between P23H and WT
rhodopsin, this would ensure any observed effect was specific
to P23H rhodopsin. These mice undergo rapid retinal degener-
ation; prior to which they express low levels of rhodopsin and
do not elaborate normal ROS disks (14,15). Therefore, an in-
crease in rhodopsin expression and/or ROS assembly would re-
veal the effect of metformin specifically on P23H synthesis,
degradation and trafficking. Daily treatment of RhoP23H/P23H
mice from P9 to P14 with metformin led to activation of AMPK
in the mouse retina, which was accompanied by an increase in
the rhodopsin protein level (Fig. 2A and B). Moreover, examin-
ation of the subcellular localisation of P23H rhodopsin showed
that P23H was localised in needle-like structures at the top of
the IS, as previously described (15), and in the IS of both un-
treated and treated mice (Fig. 2C). Treatment with metformin
appeared to result in less IS staining and an increased localisa-
tion at the needle-like structures, which were increased in size.
Indeed, co-localisation studies using Pearson’s and Mander’s
coefficients and the ER marker calnexin showed significant re-
duction in co-localisation of the two proteins in the IS of
metformin-treated retina compared to vehicle-treated retina
(Fig. 2C and D), whereas staining with prominin-1 that is local-
ised at the base of ROS, showed a significant increase of co-
localisation between P23H rhodopsin and prominin-1 in
metformin-treated retina (Fig. 2E and F). Collectively, these data
show that metformin stimulates P23H rhodopsin trafficking in
the RhoP23H/P23H mouse model.
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Figure 1. Metformin improves P23H rod opsin traffic and folding and reduces P23H-induced cell death. (A) SK-N-SH cells transfected with WT-GFP rod opsin (green) or
P23H-GFP rod opsin (green) were treated with metformin (1 mM) for 18 h. Fixed, non-permeabilised cells were stained with Rho-4D2 antibody against the extracellular
N-terminus (red). Confocal microscopy imaging under identical conditions. Scale bar: 10 lm. Boxed regions show higher magnification. (B) Immunoblot with an anti-
phospho-AMPKa (p-AMPKa) or an anti-AMPKa antibody. b-Tubulin was used as a loading control. Untreated- (C) and metformin- (þMET) treated P23H-GFP cells were
blotted with the Rho-1D4 antibody. (C) In-cell western analysis of HA-P23H rod opsin. SK-N-SH cells were fixed and immunostained with an HA antibody against the
extracellular N-terminus of rod opsin. The non-permeabilised (cell surface) immunoreactivity was determined as a percentage of total permeabilised immunoreactiv-
ity. The data were normalised to the amount of cell surface HA-WT rod opsin, values6SEM, n4, **P<0.01, unpaired two-sided Student’s t test. (D-E) Rhodopsin in-
ternalisation assay in HA-WT or HA-P23H SK-N-SH untreated cells or metformin treated (18 h). Live cells were incubated with an HA antibody for 30 min at 37 C,
washed, media returned and rod opsin was allowed to internalise for 0, 1 and 3 h. (D) Cell surface rod opsin staining at time 0. Values6SEM, n 3, ***P<0.001, unpaired
two-sided Student’s t test. (E) Remaining cell surface WT or P23H rod opsin staining after 0, 1 and 3 h of internalisation in the presence or absence of metformin, nor-
malised to time 0. Values6 2SEM, n3. (F) LDH assay on cells expressing P23H-GFP rod opsin treated with 1 mM metformin (þMET). Average absorbance values6SEM,
n3, *P< 0.05, unpaired two-sided Student’s t test. The LDH positive control (100% cell death) was 2.3 absorbance units. (G) UV-visible absorption spectra of immunoaf-
finity purified WT (black) and P23H (blue) rhodopsin pigments obtained from tetracycline inducible HEK293S cell lines treated with 300lM metformin (red) for 24 h dur-
ing expression The WT sample was diluted to show the profile on a similar scale.
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Metformin impairs photoreceptor function and survival
in P23H rodent models
As these data showed that metformin could improve mutant
P23H rod opsin traffic both in vitro and in vivo and improve cell
viability in cell culture, we next investigated the effect of metfor-
min in the P23H-1 transgenic rat. This model undergoes a rapid
retinal degeneration with a 25% photoreceptor loss by postnatal
day 15 (P15) as compared to WT rats (39). Despite this rapid de-
cline in number of photoreceptors, we had previously identified
a therapeutic window between P21 to P35 to test the ability of
drugs to improve retinal function and preserve photoreceptor
survival (22,23). Therefore, rats were treated daily from P21 to
P35 with 300 mg/kg metformin by intraperitoneal (IP) injection.
Previously, it was shown that a relatively high dose of metfor-
min must be administered for rodents to achieve plasma met-
formin concentrations similar to those found in humans and to
produce a therapeutic effect in a diabetic state (40–42). At P36,
following two weeks of treatment, rats were anaesthetised with
an IP injection of ketamine/xylazine before they were subjected
Figure 2. Increased levels of P23H in the ROS of RhoP23H/P23H mice after metformin treatment. (A) Retinal extracts from metformin- (þ) or vehicle- treated (-) RhoP23H/
P23H(P14) KI mice were western blotted with anti-rhodopsin Rho-1D4 antibody and p-AMPKa or anti-AMPKa antibody. b-Tubulin was used as a loading control.
(B) Quantification of p-AMPKa and rhodopsin levels in the RhoP23H/P23H KI mouse retina relative to b-tubulin. Densitometric analysis was used to calculate the levels of rhod-
opsin in metformin-treated mice relative to vehicle; values are means 6 SEM, n3 biological replicates. (C) Subcellular localisation of rhodopsin (green) and the ER marker
calnexin (red) in the retina from RhoP23H/P23H KI mice treated with either vehicle-PBS or metformin. Scale bar 10 mm. (D) Rhodopsin-calnexin IS staining quantified by calcu-
lating the Pearson’s and Mander’s co-localisation co-efficients using the JaCOP plug-in and ImageJ software, n¼18 images each from 2 vehicle-treated mice and 2 metfor-
min-treated mice. Values are means 6 SEM, *P<0.05, **P<0.01, unpaired two-sided Student’s t test. (E) Subcellular localisation of rhodopsin (green) in RhoP23H/P23H KI mice
retina treated with vehicle or metformin in relation to prominin 1 (red). Arrows highlight small OS, boxed area shown in close up below. Scale bar: 10 mm. (F) Rhodopsin-
prominin 1 (Prom1) staining was quantified by calculating the Pearson’s and Mander’s co-localisation co-efficients using the JaCOP plug-in and ImageJ software, n¼9 tech-
nical replicates/condition from 2 biological/condition. Values are means6 SEM, **P<0.01, ***P<0.001, unpaired two-sided Student’s t test.
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to full field scotopic electroretinography (ERG) for assessment of
visual function. Metformin treatment produced increased AMPK
phosphorylation in rat retina (Fig. 3A and B). Surprisingly, photo-
receptor function was decreased by metformin treatment, as
evidenced by lower ERG responses with both scotopic a-wave
and b-wave response amplitudes being reduced compared to
those of vehicle-treated animals (Fig. 3C–E).
Optical coherence tomography (OCT) was used to image the
retinal layers of vehicle- and metformin-treated rats and meas-
ure the thickness of the outer nuclear layer (ONL) as a marker
for photoreceptor survival. As reported previously, the superior
retina of P23H-1 rats was more damaged than the inferior (43);
however, metformin treatment caused a reduction in the thick-
ness of the ONL in the inferior retina compared to the ONL
thickness of vehicle-treated rats (Fig. 4A). A longer treatment
with metformin up to 7 weeks of age (P21–P49) confirmed a re-
duction in ONL thickness (Fig. 4B) and a significant reduction in
the average ONL thickness in metformin-treated rats (Fig. 4C).
These results suggest that metformin accelerates photoreceptor
loss in the P23H-1 rats at a relatively constant rate and indicates
that the increase is approximately equivalent to two weeks of
degeneration.
To confirm the OCT reductions, we examined the ONL in
metformin- and vehicle-treated eyes at P36 in semi-thin resin-
embedded sections (Fig. 4D). Quantitation of the number of
photoreceptor nuclei per column of the ONL in the 6 mm long
retina showed a significant reduction of photoreceptor numbers
in metformin-treated rats (Fig. 4E). This was accompanied with
a significant reduction of the ROS length (Fig. 4F). Overall, these
data suggest that metformin treatment results in enhanced
photoreceptor loss accompanied by a reduction in P23H-1 visual
function.
This effect of metformin on P23H rhodopsin expressing
photoreceptors was confirmed by treating heterozygous P23H
KI mice (RhoP23H/þ). These mice have the same gene dosage
as affected human RP individuals and are potentially a more
accurate model without any overexpression artefacts, but
they have been less widely used than the P23H-1 rats.
Histological analyses revealed that treatment with metfor-
min from P21 to P45 led to a significant decrease in ONL thick-
ness (Fig. 4G and H), confirming that metformin enhances
retinal degeneration.
To exclude the possibility that the effect of metformin is a
result of general ocular toxicity in the retina, Sprague Dawley
(SD) WT rats were treated daily with 300 mg/kg metformin or
vehicle from P21 to P35 daily and ERG and OCT tests were per-
formed at P36. Similar to the treatment of P23H-1 rats, metfor-
min treatment enhanced AMPK phosphorylation in the retina
(Supplementary Material, Fig. S4A and B). However, this was not
accompanied with a reduction in the ERG responses, as both a-
wave and b-wave amplitude responses between metformin and
vehicle-treated rats were indistinguishable (Supplementary
Material, Fig. S4C and D). Additionally, metformin did not affect
photoreceptor survival up to P36 since no difference in the
ONL thickness was observed (Supplementary Material, Fig. S4E
and F).
Figure 3. Metformin impairs photoreceptor function in P23H-1 rats. P23H-1 rats were treated from P21-P35 with either 300 mg/kg metformin or vehicle-PBS adminis-
tered daily via IP injection. (A) Retinae of metformin- (þ) or vehicle- treated (-) P23H-1 rats were western blotted with p-AMPKa or an anti-AMPKa antibody to confirm
the activation of AMPKa protein in the rat retina after metformin treatment, as indicated. b-Tubulin was used as a loading control. (B) Quantified expression levels of
AMPKa and p-AMPKa in P23H-1 retina relative to b-tubulin. Densitometric analysis was used to calculate the levels of AMPKa and p-AMPKa relative to the vehicle con-
trol; values are means 6 SEM, n  3 biological replicates. (C-E) Scotopic ERG responses; (C) average at 0 log cds/m2, (D) a-wave, (e) b-wave of P23H-1 rats (P36) treated
with either 300 mg/kg metformin (n¼16 biological replicates) or vehicle-PBS (n¼14 biological replicates), values are means 6 SEM. *P<0.05, unpaired two-sided
Student’s t test.
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These data showed that metformin does not affect a healthy
retina. To confirm the toxicity was specific to rhodopsin, and
rule out the possibility that metformin could accelerate photo-
receptor cell death in the presence of another cause of retinal
degeneration, we investigated the effect of metformin in the
rhodopsin knock out (KO) (Rho/) mouse model that does not
elaborate ROS and its photoreceptors die within three months
(44). Mice were treated daily with metformin or vehicle from
P21 to P35 and their cone visual function and photoreceptor sur-
vival was addressed at P36 by performing photopic ERG
and OCT, respectively (Supplementary Material, Fig. S4G–I).
Metformin treatment did not affect photoreceptor function
(Supplementary Material, Fig. S4G) or survival (Supplementary
Material, Fig. S4H and I), confirming that the adverse effects of
metformin in the P23H-1 rat model and P23H KI mouse model
are specific to rhodopsin and not a general feature associated
with retinal degeneration.
Metformin reduces the unfolded protein response (UPR)
in the retina of P23H-1 rats
The ER retention of mutant rhodopsin induces the unfolded
protein response (UPR) in P23H-1 rats (9,23). Therefore, we
investigated whether metformin could ameliorate the ER stress
associated with P23H misfolding. Western blot analysis showed
that the induction of IRE1 and PERK branches of the UPR were
reduced in metformin-treated rats, while there was no change
in the induction of the ATF6 branch (Fig. 5A and B). These data
in combination with an accompanied reduction in the BiP levels
support a reduction in ER stress, which would correlate with an
improvement in rhodopsin folding upon metformin treatment
and potentially also alleviate any reduction in translation asso-
ciated with PERK activation.
Furthermore, a sedimentation assay of the retinae of metfor-
min and vehicle-treated P23H-1 rats showed no major dif-
ferences in soluble (Fig. 5C) or insoluble (Fig. 5D) rhodopsin
fractions, suggesting that metformin treatment did not have a
significant effect on the rhodopsin expression level or
aggregation.
Improvement of P23H trafficking after metformin
treatment is associated with disorganised rod outer
segments (ROS)
To further investigate rhodopsin localisation, retinae of vehicle-
and metformin-treated P23H-1 rats were subjected to immuno-
histochemical analysis at P36. In metformin-treated rats, rhod-
opsin was mainly localised in ROS with less staining observed
around the nuclei in cell bodies of the ONL compared to vehicle-
treated rats (Fig. 6A). Furthermore, quantification of fluores-
cence intensity in the ROS revealed a significant increase in
rhodopsin in the ROS, supporting improved traffic (Fig. 6B). The
potential improvement of mutant rhodopsin trafficking or
enhanced degradation of mutant ER-retained rhodopsin was
further investigated by staining with the ER marker calnexin
(Fig. 6C). In the untreated retina, calnexin co-localised with
rhodopsin in the ER. This co-localisation was significantly
reduced in metformin-treated rats as measured with Pearson’s
and Mander’s coefficients suggesting that more rhodopsin traf-
ficked beyond the ER after metformin treatment (Fig. 6D). The
Figure 4. Metformin treatment accelerates photoreceptor loss in P23H rodent models. (A-C) ONL thickness of P23H-1 rats treated from P21-P35 (A) or from P21-P49 (B)
with either 300 mg/kg metformin or vehicle-PBS daily via IP injection. P23H-1 ONL thickness at P36 (A) for metformin-treated (n¼ 8 biological replicates) or vehicle-PBS
treated rats (n¼6 biological replicates) or P49 (B) (7 weeks of age) for metformin-treated (n¼5 biological replicates) or vehicle-PBS treated rats (n¼5 biological replicates)
as assessed by OCT measurements across the inferior-superior meridian. Results are either expressed as a spider plot from the optic nerve head (ONH) (A-B) or as
mean ONL thickness across the whole retina (C). Values are means 6 SEM. **P<0.01, unpaired two-sided Student’s t test. (D) Representative images of semi-thin resin
retinal sections from P23H-1 (P36) rats treated with vehicle or metformin. Sections were stained with toluidine blue. Scale bar: 10lm. (E-F) Quantification of (E) number
of nuclei/column across the retina of vehicle- or metformin-treated P23H-1 rats at P36 (n  4 biological replicates). (F) ROS length analysis was assessed within five
images of20 ROS across the retina from 3 animals per treatment. Values are means 6 SEM. *P< 0.05; **P<0.01, unpaired two-sided Student’s t test.
(G) Representative retinal images of P23H heterozygous KI (RhoP23H/þ; P45) mice treated with vehicle or metformin, as indicated. Subcellular localisation of rhodopsin
stained with Rho 1D4 antibody. Nuclei stained with DAPI. Scale bar: 10 mm. (H) Quantification of mean RhoP23H/þ ONL thickness across the whole retina of 4 animals per
treatment. Values are means6 SEM. *P<0.05.
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overall level of rhodopsin was not significantly altered (Fig. 5C
and D), suggesting that a reduction in rhodopsin caused by the
loss of photoreceptors (Fig. 4E) might be offset by an increase of
rhodopsin in the remaining rods, and there is no enhanced deg-
radation of rhodopsin.
Studies in the P23H KI mouse model have shown disk disor-
ganisation due to the presence of P23H rhodopsin in ROS, sug-
gesting that disk destabilisation could be a potential
mechanism of photoreceptor degeneration (14,15). To explore
the possibility that improved traffic of mutant rhodopsin might
further compromise ROS structure, transmission electron mi-
croscopy (TEM) was used to analyse the ROS in more detail at
P36. TEM revealed that metformin-treated P23H-1 rats had
shorter, more fragmented ROS and more disoriented and
loosely packed disks compared to their vehicle-treated controls
(Fig. 6E).
P23H rod opsin is intrinsically unstable (45,46). Even though
its folding can be partially rescued with 11- or 9-cis retinal added
during biogenesis (6,19,20), this mutant pigment remains un-
stable and defective (46). Thus, we predicted that the
metformin-rescued P23H rhodopsin would also be unstable. Our
analyses of the thermal stability of P23H rod opsin synthesised
in metformin treated cells revealed that the reconstituted pro-
tein pigment was as unstable as the 11-cis-retinal rescued P23H
pigment (Fig. 6F, Table 1).
Discussion
The manipulation of proteostasis represents a potential tool for
the treatment of misfolded protein diseases, such as misfolded
rod opsin based RP. The general aim is to improve protein fold-
ing, inhibit aggregation or promote degradation of proteins.
Among these strategies, correcting protein folding has been the
most challenging. Although pharmacological chaperones such
as retinoids or non-isomerisable retinoid analogues can assist
the trafficking and folding of P23H rod opsin in cell culture sys-
tems (18,19,47), they have limitations in vivo. One of the draw-
backs is that 11-cis retinal is already present at high levels in the
retina and increasing the amount of retinoid availability, in
combination with light exposure could result in artificially high
levels of all-trans retinal, which is toxic to photoreceptors (48).
Retinoids also lose efficacy when bleached and since they do
Figure 5. Metformin reduces the unfolded protein response (UPR) and does not affect the levels of rhodopsin in the retina of P23H-1 rats. (A) Retinae of P23H-1 rats
treated from P21-P35 with either 300 mg/kg metformin or vehicle-PBS were analysed with markers of the three UPR branches and blotted with antibodies against BiP,
p-IRE1, IRE1, p-eIF2A, eIF2a, and ATF6 cleaved or nuclear (N). Actin was used as a loading control. (B) Densitometric analysis was used to calculate the levels of BiP, p-
IRE1, IRE1, p-eIF2A, eIF2a, and ATF6 (N) relative to vehicle after normalisation to actin; values are means 6 SEM, n  3 (biological replicates). (C and D) Retinae of P23H-1
rats treated from P21-P35 with either 300 mg/kg metformin or vehicle-PBS were analysed by a sedimentation assay. Fractions were immunoblotted with the 1D4 anti-
body against rhodopsin. Densitometric analysis was used to calculate the levels of (C) soluble rhodopsin relative to the vehicle treated and (D) insoluble rhodopsin rela-
tive to the vehicle after normalisation to soluble rhodopsin. Values are means 6 SEM, n  4 (biological replicates).
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Figure 6. Improvement of rhodopsin trafficking correlates with disorganised ROS in the retinae of P23H-1 metformin-treated rats. (A) Representative retinal images of
P23H-1 (P36) rats treated with vehicle or metformin, as indicated. Subcellular localisation of rhodopsin stained with Rho 1D4 antibody. Scale bar: 10 mm. (B)
Quantification of rhodopsin immunofluorescence intensity in the ROS. A line scan was performed and the mean maximum intensity was assessed within 12 images
of15 ROS from three animals per treatment. Values are means 6 SEM, *P<0.05. (C) ONL staining of rhodopsin (green) and the ER marker, calnexin (red). Scale bar 10
mm. (D) Rhodopsin-calnexin ONL overlap was quantified by calculating the Pearson’s and Mander’s co-localisation co-efficients, using the JaCOP plug-in and ImageJ
software, n¼15 images each from two vehicle-treated rats and two metformin-treated rats. Values are means 6 SEM, **P<0.01, ***P<0.001, unpaired two-sided
Student’s t test. (E) Representative TEM images of vehicle- and metformin-treated P23H-1 retina at P36 illustrating the structure of ROS. Scale bar: 500 nm. ROS, rod
outer segment; CC, connecting cilium/cilia; IS, photoreceptor cell inner segment. (F) Rhodopsin thermal stability at 37 C. Purified WT or P23H mutant pigments from
transfected HEK-293S cells following biosynthetic treatment with either metformin (red circles or red squares) or 11-cis retinal treatment (black triangles). WT pigment
from non-treated cells (black circles). Pigments were held at 37 C (equilibrated for 2 min) before commencing repeated scans by UV-visible absorbance spectroscopy
(650–250 nm) at 30 min intervals for at least 4 h. Spectra were normalised at 650 nm and 280 nm and the change in A500 nm was plotted as a function of time. All data
were fitted with exponential decay function using SigmaPlot 12 in order to determine half-life values.
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not discriminate between opsins any locked forms could poten-
tially affect cone opsin function. A clinical trial of high dose
vitamin A supplementation produced modest clinical improve-
ments in RP patients (49). These studies were done in non-
genotyped RP patients, so it is unclear whether these included
patients with P23H rhodopsin, other rhodopsin mutations, or
patients with other retinal dystrophies. Moreover, studies in the
VPP mouse model of P23H RP showed that retinal degeneration
was slower when variants of retinal isomerase RPE65 that pro-
duce lower levels of 11-cis retinal were present, suggesting that
high levels of retinoids or retinal analogues might actually be
deleterious for such forms of RP (50).
To investigate an alternative method of promoting P23H
folding, we tested whether altering the rate of translation could
reduce the production of misfolded polypeptides during biogen-
esis, by providing the P23H intradiscal domain with more time
to fold properly and allow the mutant protein to exit from the
ER (27,28). Indeed, overnight treatment of P23H rod opsin cells
cultured with the AMPK activators, metformin or AICAR, or the
translation elongation inhibitor emetine improved P23H traf-
ficking to the plasma membrane. The AMPK activators reduced
the phosphorylation of S6, S6K and eIF4B presumably through
the mTOR signalling pathway, which could lead to altered rates
of protein translation. Importantly, the improved traffic of mu-
tant rod opsin correlated with an enhanced formation of folded
photopigment. These results are in line with the study by
Meriin and colleagues, who showed that mild inhibition of pro-
tein translation by emetine can improve the folding of mutant
DF508-CFTR (28), but this is the first time is has been shown for
AMPK activators. Previously, it was shown that autophagy
inducers such as rapamycin, which also negatively regulates
the mTOR pathway, could reduce P23H inclusion incidence
and cell death, but failed to promote the translocation of P23H
to the plasma membrane (19), suggesting that metformin and
rapamycin act via different mechanisms, as reported in other
studies (51).
Thus, we tested the potential of metformin to promote P23H
folding in the P23H-1 rat model as a therapeutic strategy to slow
down retinal degeneration. Despite some controversy about the
ability of metformin to cross the blood brain barrier (52,53), sys-
temic administration of metformin to rats and mice led to acti-
vation of AMPK in the retina suggesting that it can cross the
blood retina barrier, as noted after subcutaneous injections of
metformin in an animal model of endotoxin-induced uveitis
(EIU) (54). But, in contrast, to the protective effect of metformin
in the P23H cell culture model, in vivo treatment with metformin
exacerbated photoreceptor cell death across the retina in P23H-
1 rats and P23H KI mice. Additionally, impairment of visual
function was greater in metformin-treated P23H-1 rats.
Importantly, the same dose range and duration of treatment in
SD rats and rhodopsin KO mice did not produce any defects in
either visual function or photoreceptor survival, suggesting that
metformin was acting exclusively through P23H rhodopsin.
Since the cell culture model lacks outer segments, we investi-
gated whether metformin mediates retinal degeneration due to
a non-ER mechanism that affects ROS. Destabilisation of ROS
has been proposed as a potential mechanism for photoreceptor
degeneration caused by a small amount of defective rhodopsin
that traffics to ROS in the P23H KI mouse model (14).
Additionally, P23H rhodopsin has been reported to escape the
ER and undergo time-dependent aggregation in the ROS of
Xenopus, which in turn destabilises rod disks possibly due to the
inherent instability of the mutant rhodopsin (55). In both cases
it is likely that pharmacological chaperone rescue by the 11-cis-
retinal present in the retina contributes to pigment formation
and traffic by the mutant rod opsin (56). Similarly, we observed
shorter and more disorganised and disorientated ROS in
metformin-treated rats. Moreover, photoreceptor survival was
particularly reduced in the inferior hemisphere of the retina
that receives more light. This suggests that the fraction of P23H
that escapes the ER quality control and traffics to ROS after
treatment is still defective, unstable and cytotoxic especially
when this P23H pigment is photobleached.
Upon purification, the metformin rescued P23H was intrin-
sically unstable, just like 11-cis retinal-rescued mutant rhodop-
sin and it is likely that once successfully transported to ROS its
stability becomes further compromised by light exposure. Thus,
enhanced folding of P23H leading to its exit from the ER and in-
corporation in the disks could exacerbate the toxic effects
observed at the level of the ROS, as seen in other animal models
(14,15,55).
Despite the pharmacological rescue of some adRP mutants
with retinoids, studies have shown that purified mutant pig-
ments are intrinsically unstable, exhibiting abnormal photo-
bleaching, metarhodopsin decay and signalling properties
(21,46). Metformin treatment did not affect the folding, photo-
bleaching profile or metarhodopsin decay of WT rhodopsin,
suggesting no direct effect or binding of metformin to rhodop-
sin. Therefore, the partial rescue of P23H folding is more likely
due to modulation of protein translation, or other pleiotropic ef-
fects, and not due to pharmacological chaperone rescue.
Several studies reported neuroprotection following pharmaco-
logically mediated AMPK activation in several neurodegenera-
tive conditions such as Parkinson’s disease, Huntington’s
disease and multiple sclerosis (57–60). Furthermore, studies on
diabetic retinopathy and EIU showed that activation of AMPK
reduced retinal inflammation (54,61,62), and that AMPK in
Drosophila protects photoreceptors from excitotoxicity and is
required to maintain neuronal integrity (63). Therefore, the pro-
tective potential of AMPK activation in the retina is strongly
supported by the above studies, whereas our data show that the
negative effect of AMPK activation in this form of RP is probably
due to the inherent structural instability of P23H rhodopsin
after rescue.
Consequently, this study highlights the need to focus our
search for pharmacological chaperones for rhodopsin RP on
allosteric correctors of misfolding, molecules unaffected by light
that could stabilise the seven-transmembrane bundle of rhod-
opsin without affecting the function of cone opsins. Such mol-
ecules might need to target the intradiscal plug and not bind
close to the retinal binding pocket, where most research efforts
have centred. They also would need to achieve high concentra-
tions in the retina (to match the level of mutant rhodopsin)
with low toxicity and last for many days, as ROS rhodopsin
takes 10 days to traffic to the RPE for degradation. Therefore, ra-
ther than improving mutant rhodopsin folding, therapeutic
Table 1. Thermal stability of WT and P23H mutant pigments in the
presence or absence of metformin during biogenesis.
Half life (t1/2) of thermal decay (min)
Mutant pigment 37 C 56.5 C
WT no treatment 8920.1 37.6
WT 300 mM metformin 8192.9 38.7
P23H 10 mM 11-cis retinal 88.8 -
P23H 300 mM metformin 75.3 -
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strategies might be better focused on clearing mutant rhodop-
sin and reducing its aggregation (22,23,64), as these homeostatic
interventions could improve photoreceptor function and sur-
vival in animal models associated with toxic gain-of-function.
Alternatively, RNA-based therapies could target mutant mRNA
(65) or CRISPR/Cas9 gene editing could be used to target the mu-
tation closer to its source.
Metformin is a relatively safe drug that is taken by over 20
million people worldwide. We have shown that it can stimulate
the improved folding of a mutant protein that is normally mis-
folded and removed by ER-associated degradation. Therefore,
metformin might be able to improve the folding of other mutant
proteins that are normally degraded. This could be particularly
useful in recessive conditions with amino acid substitutions
that result in protein misfolding, degradation and loss of func-
tion (e.g. cystic fibrosis or recessive RP), where the restoration of
some protein function might be sufficient to ameliorate disease.
In dominant toxic gain-of-function diseases, however, reducing
the ability of the protein quality control machinery to remove
mutant proteins could exacerbate gain-of-function defects. As
such, metformin could potentially exacerbate disease progres-
sion in rhodopsin RP patients with the P23H mutation and pos-
sibly other rhodopsin misfolding mutations, if they are
prescribed for type II diabetes. This potential complication
needs to be considered in terms of patient’s overall health and
the risk to retinal function posed by uncontrolled diabetes, but
other approaches might prove suitable for controlling patient’s
diabetes without compromising retinal health.
Methods
Animals
All animal procedures were conducted according to the Home
Office (UK) regulations, under the Animals (Scientific
Procedures) Act of 1986, and with the approval of the local UCL
Institute of Ophthalmology, London, UK ethics committee. The
P23H-1 line rats were kindly provided by Professor Matt LaVail,
(University of California San Francisco, USA, http://www.ucs
feye.net/mlavailRDratmodels.shtml) and crossed with wild-
type Sprague Dawley (SD rats) to generate heterozygous P23H-1
rats. SD rats were purchased from Harlan (Blackthorn, UK).
P23H KI mice were generated as previously described (14).
Rhodopsin KO mice (rho/) were provided by Professor Peter
Humphries (Trinity College, Dublin, Ireland). All animals were
housed under a 12 h light (20–100 lux): 12 h dark (<10 lux) cycle,
with food and water available ad libitum. Both sexes were used
evenly for experiments.
Drug treatments
P23H KI homozygous mice were moved to a dark cabinet at P0
and treated from P9 to P13 with either 300 mg/kg metformin
(1,1-dimethylbiguanide hydrochloride, Sigma Aldrich, D5035) or
vehicle. The intraperitoneal (IP) injections were carried out daily
under red-light conditions and mice were humanely killed at
P14 by cervical dislocation.
P23H-1 rats were treated from postnatal day P21 to P35 (5
weeks of age) or P21 to P49 (7 weeks of age); SD rats and rhodop-
sin KO mice were treated from postnatal day P21 to P35 P23H KI
heterozygous mice from P21 to P45. Vehicle, 300 mg/kg (rats and
RhoP23H/þmice) or 250 mg/kg (Rho-/- mice) of metformin was ad-
ministered daily via IP injection. The dose was reduced for later
mouse treatments because of potential general toxicity.
Animals were monitored daily for any adverse effects and for
body weight gain. At P36 or P49 rats were anaesthetised with
ketamine/xylazine at 0.2 ml/100 g and mice with ketamine/
domitor at 0.08 ml/10 g administered via an IP injection and
were subjected to ERG and OCT before they were humanely
killed by cervical dislocation.
Electroretinography (ERG)
At P35 or P49, rats were dark-adapted overnight in a ventilated
light-tight box. Scotopic electroretinogram tests were carried
out under red-light conditions as described in (66). Briefly,
pupils were dilated with topical 1% tropicamide (mice) or and
1% tropicamide and 2.5% phenylephrine hydrochloride (rats).
Full-field scotopic ERG’s were obtained by using the Diagnosys
system and Espion software (Diagnosys). Animals were dark-
adapted for a further 10 min and simultaneous bilateral record-
ing flash stimuli (10 ms to 1 ms duration, repetition rate 0.2 Hz)
were presented via an LED stimulator (log intensity 5 toþ 1)
under scotopic conditions. For the Rho KO mice simultaneous
bilateral recording flash stimuli (0.1 ms to 30 ms duration, repe-
tition rate 0.2 Hz) were presented via an LED stimulator (log in-
tensity -1 toþ 3) under photopic conditions.
Optical coherence tomography (OCT)
Animals were anaesthetised and their retinae were imaged
using the Bioptigen Envisu R2300 Spectral-domain ophthalmic
imaging system (SDOIS). To prevent cornea desiccation during
the procedure, topical Systane Ultra (Alcon) lubricant eye drops
were applied bilaterally every minute. Following lubrication, the
rats were positioned for imaging in the animal imaging mount-
rodent alignment stage (AIM-RAS). The front teeth of the rat
were gently placed over the bite bar and a band was placed over
the nose to ensure restriction of movement. The animals were
positioned so that the images were centred to the optic nerve
head. Images were acquired by the InVivoVue Clinic application
using a rectangular scanning protocol consisting of a either a
2 mm by 2 mm perimeter with 750 A-scans (lines) and 5 B-scans
(frames) with a 60 frames/B-scan (for rat retina) or 1.4 mm by
1.4 mm perimeter with 750 A-scans (lines) and 10 B-scans
(frames) with a 20 frames/B-scan (for mouse retina). All OCT
images were averaged using the InVivoVue software to obtain a
better image resolution. Following OCT analysis rats were hu-
manely killed by cervical dislocation. The Bioptigen InVivoVue
Diver 2.0 was used to enable manual segmentation of the retinal
layers and the outer nuclear layer thickness was measured after
exporting results from Diver to Excel.
Western blotting and sedimentation assay
Retinae were extracted and lysed with ice-cold RIPA buffer
(50 mM Tris-HCl pH8, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1%
SDS and 0.05% sodium deoxycholate) containing 2% (v/v) mam-
malian protease inhibitor cocktail 2% (v/v) mammalian phos-
phatase inhibitor cocktail (Sigma Aldrich). Retina lysates were
sonicated for 2  30 s centrifuged for 15 min at 12,000  g and at
4C and diluted in sodium dodecyl sulfate (SDS) sample loading
solution (0.0625 M Tris pH 6.8, 2% (w/v) SDS, 30% (v/v) glycerol,
20% (v/v) b-mercaptoethanol). The rhodopsin sedimentation
assay in P23H-1 rat retinae was performed as previously
described (22). For cellular studies, cell lysates were prepared as
previously described (67). Samples for rod opsin were not heat
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denatured, whereas samples for all the other antigens were
heated at 95C for 5 min before resolving by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and western blotting. Proteins
were transferred to nitrocellulose in 25 mM Tris, pH 8.3, 192 mM
glycine, 0.01% SDS (w/v) and 20% (v/v) methanol. To prevent
non-specific binding, membranes were first blocked at 4C with
either 5% (w/v) Marvel Milk in PBS with 0.1% (v/v) Tween buffer,
pH 7.5 or 5% (w/v) bovine serum albumin (BSA) in TBS, pH 7.5,
with 0.1% (v/v) Tween buffer. Immunodetection of proteins of
interest was carried out with the following primary antibodies:
mouse anti-Rho-1D4 (1:1000 from Professor Robert Molday
(Department of Biochemistry and Molecular Biology, University
of British Columbia, Canada), mouse anti-b-tubulin
(1:3000;clone TUB 2.1, T4026, Sigma Aldrich), rabbit anti-phos-
pho-AMPKa (Thr172) (1:1000, 40H9, 2535S, New England Biolabs
(NEB), anti-rabbit AMPKa (1:1000, D63G4, 5832S, NEB), anti-
phospho-S6 Ribosomal Protein (Ser235/236), (p-rpS6 Ser 235/236),
(1:1000, 4858, NEB), anti-phospho-S6 Ribosomal Protein (Ser240/
244) (p-rpS6 Ser 240/244), (1:1000, 5364, NEB), anti-phospho-p70 S6
Kinase (Thr389), (p-p70S6K Thr 389) (1:1000, 108D2, 9234, NEB),
p70 S6 Kinase (1:1000, 49D7, 2708, NEB), 4E-BP1 (1:1000, 53H11,
9644, NEB), 4EBP1 (1:1000, 53H11, 9644, NEB), anti-actin (1:2000,
Millipore), PERK (1:1000, NEB), eIF2a (1:1000, NEB), BiP (1:2000,
Sigma Aldrich), anti-phospho eIF2a (pSer51) (1:1000, Sigma
Aldrich), IRE1 and anti-phospho IRE1 (1:1000, NEB), ATF6 (1:1000,
Santa Cruz). Blots were probed with either goat anti-rabbit
(1:30000; 32460, ThermoFisher Scientific) or anti-mouse
(1:50000; 32430, ThermoFisher Scientific) secondary antibodies.
Proteins were detected with the ECL Plus reagent (GE
Healthcare) or ECL prime (VWR).
Immunohistochemistry
For outer segment measurement studies, tissue was prepared
as previously described (23). Semi-thin and ultra-thin sections
were cut with a Leica Ultracut S microtome fitted with an appro-
priate type of diamond knife. For light microscopy semi-thin
sections were stained with 1% toluidine blue and 1% borax in
50% ethanol. Ultra-thin sections were treated for 5 min with 1%
uranyl acetate in 50% ethanol followed by Reynold’s lead citrate,
prior to viewing and photography with a JEOL 1010 TEM operat-
ing at 80 kV.
For fluorescence studies, eyes were collected at specified
time points and fixed overnight in 4% paraformaldehyde at 4 C.
Post-fixation eyes were cryoprotected by incubation in 30% su-
crose in PBS. Eyes were then frozen and cyrosectioned as previ-
ously described (22). Cryosectioned eyes were stained with
mouse anti-Rho-1D4 (1:1500), rabbit anti-calnexin (1:600; C4731,
Sigma Aldrich) and rat anti-prominin-1 (1:200; clone 13A4,
CD133, eBioscience) primary antibodies in blocking solution (3%
BSA, 10% normal goat serum) and visualised with Alexa Fluor
488 (1:1000; A11001/A11005, Life Technologies Ltd) and 594
(1:1000; A11007, Life Technologies Ltd) conjugated IgGs. 4’,6-dia-
midino-2-phenylindole dihydrochloride (DAPI) (Sigma Aldrich)
staining was used to visualise the nuclei.
Fluorescence imaging and analysis
Retina images were obtained using a Carl Zeiss LSM700 laser-
scanning confocal microscope whereas images for nuclei/col-
umn and ROS length analysis were taken on a Carl Zeiss
LSM510 confocal microscope. Images were exported with Zen
2009 software were then prepared using Adobe Photoshop and
Illustrator CS4. All measurements were performed in ImageJ
(http://rsbweb.nih.gov/ij/). The Pearson’s and Mander’s co-
localisation co-efficients in cells co-stained using Rho-1D4 and
either anti-calnexin or anti-prominin-1 was measured with
JaCOP plug-in and ImageJ software. The relative amounts of
rhodopsin present in treated and untreated OS were assessed
by comparing the fluorescent intensity measured in line scans
generated using fixed detector gain and offset settings previ-
ously set up to yield non saturated images of the brightest
treated specimens. The hardware was set up to acquire 2K
images at 1 Airy unit resolution (0.8um @ l488 nm, NA¼ 1.4). An
intensity distribution across the Z axis of the line scan was then
generated using the ImageJ profile tool and the maximum in-
tensity across the ROS averaged.
Cell culture, transient transfection and drug treatments
SK-N-SH human neuroblastoma cells were maintained and
transfected essentially as previously described (68). The WT-
GFP and P23H-GFP rod opsin plasmids in pEGFP-N1 vector were
prepared as previously described (6). After 3 h transfection and
2 h recovery in serum, cells were either left untreated or treated
with 1 mM metformin or 2 mM AICAR (Sigma Aldrich, A9978) for
18 h at 37C. HEK293S human embryonic kidney cells provided
by J. Nathans (John Hopkins School of Medicine) were main-
tained and transfected essentially as previously described (46).
HEK293S cells expressing the WT or P23H mutant bovine rod
opsin genes were treated with 11-cis retinal provided by Rosalie
K Crouch (Storm Eye Institute, Medical University of South
Carolina) during receptor biosynthesis as described in (46) ex-
cept that 10 mM of 11-cis retinal (final concentration) was added
as one installment in the dark. Metformin also was added only
once to cells at a final concentration of 300 mM. Cells were har-
vested 24 h post treatment.
HEK 293S stable cell lines
Tetracycline-inducible WT and P23H mutant rod opsin genes
were constructed by previously described procedures (38). Opsin
expression was induced by the addition of 2 lg/ml tetracycline
after which 11-cis retinal (10 mM), metformin (300 mM) or AICAR
(2 mM) treatments were immediately initiated.
Rod opsin cell surface expression by in-cell western
SK-N-SH cells were seeded in 24-well plates and transfected
with HA-WT or HA-P23H rod opsin a gift of Professor Yuichi
Hashimoto (The University of Tokyo) (69). Three hours after
transfection and 2 h after recovery in serum, cells were either
left untreated or treated with 1 mM metformin, 2 mM AICAR,
100 nM and 300 nM cycloheximide (CHX, Sigma Aldrich, C7698)
or 100 and 300 nM emetine (Sigma Aldrich, E2375). Following
18 h treatment at 37C, cells were washed with PBS and fixed in
4% PFA for 10 min. Cells were permeabilised with 0.25% Triton
X-100 for 10 min to assay total cellular rod opsin levels or left
unpermeabilised to detect rod opsin cell surface expression.
Cells were then blocked with 3% BSA and 10% normal goat
serum for 1.5 h, followed by incubation with anti-HA antibody
(1:500, H6908, Sigma Aldrich) for 1 h. Cells were then washed
with PBS and incubated with IRDye 680 secondary antibody
(1:1000, LI-COR) for 1 h protected from light. Cells were washed
and fluorescent signal measured using a LI-COR Odyssey plate
reader.
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Lactate dehydrogenase (LDH) cell death assay
The LDH assay was performed in SK-N-SH cells essentially as
previously described (70) starting 48 h after the addition of 1 mM
metformin or 2 mM AICAR following the manufacturer’s
instructions.
Rod opsin internalisation assay
SK-N-SH cells were seeded in 24-well plates and transfected
with HA-WT or HA-P23H rod opsin. Three hours after transfec-
tion and 2 h recovery in serum, cells were either left untreated
or treated with 1 mM metformin. Following 18 h treatment live
cells were incubated with a mouse HA antibody (1:500, H6908,
Sigma Aldrich) or HA and metformin in culture media at 37C to
label rod opsin at the cell surface. Following 30 min incubation
cells were washed with PBS, the medium was replaced to allow
rod opsin endocytosis and the cells incubated for 0, 1 and 3 h.
Cells were fixed in 4% PFA, were not permeabilised in order to
detect exclusively rod opsin cell surface expression and blocked
with 3% BSA and 10% normal goat serum for 1 h followed by in-
cubation with IRDye 680 secondary antibody (1:1000, LI-COR) for
1 h protected from light. Cells were then washed and fluores-
cent signal measured using a LI-COR Odyssey plate reader.
Immunofluorescence in cells
Immunofluorescence assays were carried out as previously
described (70). The mouse anti-Rho-4D2 (1:300; MABN15) anti-
body was from Millipore. Fluorescence was observed with a Carl
Zeiss LSM 700 confocal laser-scanning microscope for image ac-
quisition. Images were exported from the LSM browser to Adobe
Photoshop for figure preparation and annotation by Adobe
Illustrator.
Immunoaffinity purification of rhodopsin
The procedure for purification of rhodopsin pigments from de-
tergent solubilised HEK293S cell extracts involving Rho-1D4
Sepharose 4B (Amersham Biosciences) has been described in
(46). Rhodopsin was eluted in 10 mM BTP (Sigma Aldrich) at pH
7.2 containing 100 mM 9 mer peptide (TETSQVAPA) correspond-
ing to the rhodopsin C-terminus (Peptide Protein Research).
UV-visible absorption spectroscopy and photobleaching
assay of rhodopsin
Procedures for UV-visible absorption spectroscopy of rhodopsin
and its photobleaching have been described in detail (46).
Thermal stability of rhodopsin and MII stability of
rhodopsin
Assays of the thermal stability of rhodopsin at 37 C were car-
ried out essentially as described in (46) except that the UV-
visible absorption spectra were acquired at 30-min intervals
over 4 h. Similarly, measurements of the rate of MII decay in
rhodopsin also were described in (46).
Statistical analyses
The values for all the experiments represent the means6SEM.
The exact number of samples is described in greater detail in
the figure legends, as it was dependent on experimental design.
All statistical analyses were performed with the unpaired two-
sided Student’s t test. A P value of less than 0.05 was considered
statistical significant.
Supplementary Material
Supplementary Material is available at HMG online.
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